259 related articles for article (PubMed ID: 18927293)
1. Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Michaelis M; Bliss J; Arnold SC; Hinsch N; Rothweiler F; Deubzer HE; Witt O; Langer K; Doerr HW; Wels WS; Cinatl J
Clin Cancer Res; 2008 Oct; 14(20):6531-7. PubMed ID: 18927293
[TBL] [Abstract][Full Text] [Related]
2. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
[TBL] [Abstract][Full Text] [Related]
3. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
4. Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
Schmidt M; Vakalopoulou E; Schneider DW; Wels W
Br J Cancer; 1997; 75(11):1575-84. PubMed ID: 9184171
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF alpha.
Schmidt M; Wels W
Br J Cancer; 1996 Sep; 74(6):853-62. PubMed ID: 8826849
[TBL] [Abstract][Full Text] [Related]
6. Pseudomonas Exotoxin A Based Toxins Targeting Epidermal Growth Factor Receptor for the Treatment of Prostate Cancer.
Fischer A; Wolf I; Fuchs H; Masilamani AP; Wolf P
Toxins (Basel); 2020 Nov; 12(12):. PubMed ID: 33260619
[TBL] [Abstract][Full Text] [Related]
7. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
Schmidt M; Maurer-Gebhard M; Groner B; Köhler G; Brochmann-Santos G; Wels W
Oncogene; 1999 Mar; 18(9):1711-21. PubMed ID: 10208432
[TBL] [Abstract][Full Text] [Related]
8. Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development.
Kellner C; Bleeker WK; Lammerts van Bueren JJ; Staudinger M; Klausz K; Derer S; Glorius P; Muskulus A; de Goeij BE; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Aug; 371(1-2):122-33. PubMed ID: 21756911
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma.
Onda M; Wang QC; Guo HF; Cheung NK; Pastan I
Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056
[TBL] [Abstract][Full Text] [Related]
10. Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.
Simon N; Antignani A; Sarnovsky R; Hewitt SM; FitzGerald D
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27075852
[TBL] [Abstract][Full Text] [Related]
11. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
Wels W; Beerli R; Hellmann P; Schmidt M; Marte BM; Kornilova ES; Hekele A; Mendelsohn J; Groner B; Hynes NE
Int J Cancer; 1995 Jan; 60(1):137-44. PubMed ID: 7814146
[TBL] [Abstract][Full Text] [Related]
12. Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins.
Schmidt M; Wels W
Int J Cancer; 2002 Jan; 97(3):349-56. PubMed ID: 11774287
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model.
Pardo A; Stöcker M; Kampmeier F; Melmer G; Fischer R; Thepen T; Barth S
Cancer Immunol Immunother; 2012 Oct; 61(10):1617-26. PubMed ID: 22350071
[TBL] [Abstract][Full Text] [Related]
14. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
Bruell D; Bruns CJ; Yezhelyev M; Huhn M; Müller J; Ischenko I; Fischer R; Finnern R; Jauch KW; Barth S
Int J Mol Med; 2005 Feb; 15(2):305-13. PubMed ID: 15647848
[TBL] [Abstract][Full Text] [Related]
15. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
16. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of a transforming growth factor-alpha--Pseudomonas exotoxin fusion protein in vitro and in vivo.
Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
J Ind Microbiol; 1991 Apr; 7(3):203-7. PubMed ID: 1367127
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effect of a fusion protein from transforming growth factor alpha and Pseudomonas exotoxin on rat and human bladder carcinoma cells in vitro.
Kameyama S; Kawamata H; Pastan I; Oyasu R
J Cancer Res Clin Oncol; 1994; 120(9):507-12. PubMed ID: 8045915
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor alpha-Pseudomonas exotoxin fusion protein prolongs survival of nude mice bearing tumor xenografts.
Heimbrook DC; Stirdivant SM; Ahern JD; Balishin NL; Patrick DR; Edwards GM; Defeo-Jones D; FitzGerald DJ; Pastan I; Oliff A
Proc Natl Acad Sci U S A; 1990 Jun; 87(12):4697-701. PubMed ID: 2352944
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
